{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:25:50Z","timestamp":1783416350114,"version":"3.54.6"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>\n                      Rheumatoid arthritis (RA) is a well-recognized risk factor for nontuberculous mycobacterial infections, especially among patients receiving glucocorticoids or biological disease-modifying antirheumatic drugs. However, cases of\n                      <jats:italic toggle=\"yes\">Mycobacterium avium<\/jats:italic>\n                      complex (MAC) pulmonary disease in RA patients without such immunosuppressive therapies are rarely reported, which challenges the conventional risk stratification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 78-year-old male with a 3-year history of RA and interstitial lung disease (ILD) presented with progressive dyspnea and chest tightness. He had no fever, joint swelling, or typical infection flares. Before admission, he was treated with Tripterygium Glycosides and Iguratimod (non-biologic, non-glucocorticoid agents).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>The patient had chest tightness and weight loss. Chest high-resolution computed tomography showed asymmetric progression of ILD, along with tree-in-bud signs, centrilobular nodules, and suspicious fibrocavities. Bronchoscopy revealed necrotizing granulomatous inflammation, and quantitative metagenomic sequencing of bronchoalveolar lavage fluid confirmed MAC (no drug-resistant genes detected).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient was put on a 4-drug anti-MAC regimen (rifampicin, azithromycin, ethambutol, amikacin). However, he was lost to follow-up after being transferred to a tuberculosis specialist hospital. He eventually died of unknown causes, and there were prior reports of his nonadherence to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>For RA patients with ILD who show asymmetric imaging progression or discordant inflammatory markers, it is crucial to actively screen for atypical pathogens like MAC, even in the absence of glucocorticoid or biologic exposure. This case highlights the necessity of expanding nontuberculous mycobacterial infection risk assessment beyond traditional immunosuppressive therapies in RA-ILD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>For patients with autoimmune disease-associated interstitial pneumonia, particularly those with progressive interstitial lung disease (ILD) despite stable autoimmune serology, proactive screening for atypical pathogens such as nontuberculous mycobacteria is critical. When imaging shows asymmetric lesions, tree-in-bud opacities, centrilobular nodules, or fibrocavitary changes, clinicians should prioritize comprehensive etiological evaluation \u2013 including bronchoscopy and histopathology \u2013 to avoid misdiagnosing these opportunistic infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048801","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:02:05Z","timestamp":1779469325000},"page":"e48801","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Mycobacterium avium complex pulmonary disease in rheumatoid arthritis-associated interstitial lung disease under non-biologic immunomodulatory therapy: A case report"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8676-4329","authenticated-orcid":false,"given":"Ruixia","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-3114","authenticated-orcid":false,"given":"Yongmei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline.","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"R2-20260707","first-page":"101","article-title":"[Chinese expert consensus on diagnosis and treatment of non-tuberculous mycobacterial pulmonary disease complicated with bronchiectasis].","volume":"48","year":"2025","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s15010-022-01890-z","article-title":"Diagnostic performance of metagenomic next-generation sequencing in non-tuberculous mycobacterial pulmonary disease when applied to clinical practice.","volume":"51","author":"Wei","year":"2023","journal-title":"Infection"},{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/s10165-004-0360-z","article-title":"Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab.","volume":"15","author":"Okubo","year":"2005","journal-title":"Mod Rheumatol"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3201\/eid1510.090310","article-title":"Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.","volume":"15","author":"Winthrop","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review.","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1128\/IAI.01606-13","article-title":"Host response to nontuberculous mycobacterial infections of current clinical importance.","volume":"82","author":"Orme","year":"2014","journal-title":"Infect Immun"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/mr\/roab032","article-title":"Rheumatoid arthritis with nontuberculous mycobacterial pulmonary disease: a retrospective, single-centre cohort study.","volume":"32","author":"Takei","year":"2022","journal-title":"Mod Rheumatol"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3109\/s10165-011-0448-1","article-title":"A case report of a patient with rheumatoid arthritis complicated with Mycobacterium avium during tocilizumab treatment.","volume":"21","author":"Nakahara","year":"2011","journal-title":"Mod Rheumatol"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12890-015-0130-z","article-title":"Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report.","volume":"15","author":"Namkoong","year":"2015","journal-title":"BMC Pulm Med"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/IDR.S343763","article-title":"Development of rheumatoid arthritis in cavitary mycobacterium avium pulmonary disease: a case report of successful treatment with CTLA4-Ig (Abatacept).","volume":"15","author":"Tanaka","year":"2022","journal-title":"Infect Drug Resis"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jgf2.99","article-title":"Disseminated Mycobacterium intracellulare infection with multiple abscesses on extremities in a woman with chronic corticosteroid therapy.","volume":"18","author":"Yaita","year":"2017","journal-title":"J Gen Fam Med"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/clinids\/17.1.7","article-title":"Mycobacterium avium complex infection and AIDS: advances in theory and practice.","volume":"17","author":"Benson","year":"1993","journal-title":"Clin Infect Dis"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14397595.2018.1452334","article-title":"Low body mass index and lymphocytopenia associate with Mycobacterium avium complex pulmonary disease in patients with rheumatoid arthritis.","volume":"29","author":"Hirose","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/art.23923","article-title":"Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out.","volume":"59","author":"Allaire","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/art.43338","article-title":"Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: a comparative cohort study.","volume":"78","author":"Zhang","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrrheum.2013.82","article-title":"Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.","volume":"9","author":"Winthrop","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/art.21353","article-title":"Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis.","volume":"52","author":"Bryl","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R19-20260707","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1378\/chest.13-2058","article-title":"Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada.","volume":"146","author":"Brode","year":"2014","journal-title":"Chest"},{"key":"R20-20260707","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-0038-1651493","article-title":"Diagnosis of nontuberculous mycobacteria lung disease.","volume":"39","author":"Cowman","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"R21-20260707","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2014.10.001","article-title":"Pathogenesis and risk factors for nontuberculous mycobacterial lung disease.","volume":"36","author":"Honda","year":"2015","journal-title":"Clin Chest Med"},{"key":"R22-20260707","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1473-3099(06)70602-8","article-title":"Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review.","volume":"6","author":"Steingart","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/QCO.0b013e3283511a64","article-title":"Therapy of refractory nontuberculous mycobacterial lung disease.","volume":"25","author":"Griffith","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"R24-20260707","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","article-title":"Mycobacterial diseases and antitumour necrosis factor therapy in USA.","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R25-20260707","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/s10165-007-0626-3","article-title":"Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.","volume":"17","author":"Koike","year":"2007","journal-title":"Mod Rheumatol"},{"key":"R26-20260707","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"R27-20260707","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British thoracic society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"R28-20260707","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/cid\/ciaa1062","article-title":"Corrigendum to: treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline.","volume":"71","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R29-20260707","doi-asserted-by":"crossref","first-page":"608703","DOI":"10.3389\/fphar.2020.608703","article-title":"Clinical practice guideline for tripterygium glycosides\/tripterygium wilfordii tablets in the treatment of rheumatoid arthritis.","volume":"11","author":"Lin","year":"2020","journal-title":"Front Pharmacol"},{"key":"R30-20260707","doi-asserted-by":"crossref","first-page":"e0253513","DOI":"10.1371\/journal.pone.0253513","article-title":"Effectiveness of drug safety measures for reducing the incidence of adverse drug reactions: post-hoc analysis of data from all-case surveillance of iguratimod using generalized estimating equations.","volume":"16","author":"Shibata","year":"2021","journal-title":"PLoS One"},{"key":"R31-20260707","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.2010.271","article-title":"Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.","volume":"89","author":"Reitman","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R32-20260707","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3904\/kjim.2023.193","article-title":"Clinical characteristics and prognostic factors of non-tuberculous mycobacterial disease in patients with rheumatoid arthritis.","volume":"39","author":"Kim","year":"2024","journal-title":"Korean J Intern Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:01:15Z","timestamp":1783414875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":32,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048801","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-09-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}